Skip to main content

Clinical Trials › NCT06700343

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsored by Amgen

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
444
Target enrollment
17
U.S. states
Jan 2025
Start date
Dec 2027
Expected completion

Interventions / Treatments

Ocrelizumab (US)Ocrelizumab (EU)ABP 692

Conditions studied

Relapsing-remitting Multiple Sclerosis (RRMS)

Where this trial is running (25 sites)

Florida4 sites
Boca Raton · Naples · Rockledge · +1 more
Colorado2 sites
Basalt · Fort Collins
Michigan2 sites
Detroit · Farmington
New Jersey2 sites
Edison · Paramus
Ohio2 sites
Columbus · Dayton
Tennessee2 sites
Knoxville · Nashville
Alabama1 site
Mobile
Arizona1 site
Scottsdale
Carlsbad
New Haven
Hawaii1 site
Honolulu
Kansas1 site
Kansas City
Albuquerque
Winston-Salem
Greenville
Texas1 site
Frisco
Wisconsin1 site
Milwaukee

MS centers in Florida

Compare treatment centers near a trial site by center type, providers and trials.

View Florida centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play